Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
aTyr Pharma revenue
aTyr Pharma's revenue is $235,000.
What is aTyr Pharma's revenue?
- ATyr Pharma's revenue growth from 2019 to 2024 is -44.31%.
- ATyr Pharma has 44 employees, and the revenue per employee ratio is $5,340.
- ATyr Pharma's peak quarterly revenue was $8.1M in 2020(q1).
- ATyr Pharma peak revenue was $10.5M in 2020.
- ATyr Pharma annual revenue for 2023 was 353.0K, -96.6% growth from 2022.
- ATyr Pharma annual revenue for 2024 was 235.0K, -33.43% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
aTyr Pharma historical revenue
ATyr Pharma's peak revenue was $10.5M in 2020. The peak quarterly revenue was $8.1M in 2020(q1).
ATyr Pharma's revenue increased from $422.0k in 2019 to $235.0K currently. That's a -44.31% change in annual revenue.
aTyr Pharma annual revenue
aTyr Pharma annual revenue over time
| Fiscal year / year | aTyr Pharma revenue |
|---|---|
| 2019 | $422,000 |
| 2020 | $10.5M |
| 2022 | $10.4M |
| 2023 | $353,000 |
| 2024 | $235,000 |
Rate aTyr Pharma's financial transparency
aTyr Pharma annual growth
ATyr Pharma saw the greatest revenue growth in 2020, when revenue increased by 2,377.49%.
ATyr Pharma had the lowest revenue growth in 2022, when revenue changed by -0.66%.
aTyr Pharma annual growth rate over time
| Year | aTyr Pharma growth |
|---|---|
| 2020 | 2377%↑ |
| 2022 | -1%↓ |
| 2023 | -97%↓ |
| 2024 | -33%↓ |
aTyr Pharma quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
aTyr Pharma quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | - | $94,000 | $184,000 | $144,000 |
| 2020 | $8.1M | $189,000 | $148,000 | $2.1M |
| 2023 | - | - | $353,000 | - |
| 2024 | $235,000 | - | - | - |
aTyr Pharma jobs nearby
Do you work at aTyr Pharma?
Did aTyr Pharma meet its revenue projections?
aTyr Pharma financial information
| CEO | Sanjay S. Shukla |
| Industry | Software & Services |
| Company Type | Public |
| Employees Number | 44 |
| Date Founded | 2005 |
| Headquarters | San Diego, California |
| Number of Locations | 1 |
| Revenue | $235,000 |
| Net Income | -$45,338,000 |
| PE Ratio | -1.84 |
| Tax Rate | 0.0% |
| Market Capitalization | $118.0M |
| Total Assets | $95,786,000 |
| Ticker | LIFE |
aTyr Pharma jobs you might like
aTyr Pharma financing
ATyr Pharma received early financing of $10.5M on 2007-04-18.
| Series | Round size | Date |
|---|---|---|
| Series B | $10.5M | 04/2007 |
| Series C | $12M | 09/2009 |
| Series C | $23M | 10/2010 |
| Series D | $49M | 07/2013 |
| Debt Financing | $10M | 07/2013 |
| Series E | $76M | 03/2015 |
| Post Ipo Debt | $20M | 11/2016 |
| Post Ipo Equity | $45M | 08/2017 |
| Post Ipo Equity | $20.7M | 03/2020 |
| Post Ipo Equity | $86.3M | 09/2021 |
aTyr Pharma investors
| Investors | Security type |
|---|---|
| Polaris Partners | Series B |
| Cardinal Partners | Series B |
| Alta Partners | Series B |
| Polaris Partners | Series C |
| Cardinal Partners | Series C |
| Alta Partners | Series C |
| Polaris Partners | Series C |
| Cardinal Partners | Series C |
| Alta Partners | Series C |
| Domain Associates | Series C |
| Polaris Partners | Series D |
| Eight Roads Ventures | Series D |
| Cardinal Partners | Series D |
| Alta Partners | Series D |
| Domain Associates | Series D |
| Silicon Valley Bank | Debt Financing |
| EcoR1 Capital LLC | Series E |
| Federated Hermes | Series E |
| Sphera Global Healthcare Fund | Series E |
| Cardinal Partners | Series E |
| Deerfield | Series E |
| SOFINNOVA INVESTMENTS INC | Series E |
| Baker Brothers Advisors LLC | Series E |
| Alta Partners | Series E |
| T. Rowe Price Group, Inc. | Series E |
| Rock Springs Capital | Series E |
| Polaris Venture Capital | Series E |
| Domain Associates | Series E |
| Solar capital | Post Ipo Debt |
| Silicon Valley Bank | Post Ipo Debt |
| Viking Global Investors | Post Ipo Equity |
| EcoR1 Capital LLC | Post Ipo Equity |
| Redmile Group | Post Ipo Equity |
aTyr Pharma competitors
ATyr Pharma's top competitor, Merck, earned an annual revenue of $64.2B.
ATyr Pharma's smallest competitor is American Society for Cell Biology with revenue of $10.0M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Regeneron | $85,589 | $14.2B | 9,123 | 295 |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 104 |
| Merrimack Pharmaceuticals | $90,170 | $102.8M | 426 | - |
| Merck | $90,328 | $64.2B | 74,000 | 1,766 |
| WebMD | $93,501 | $705.0M | 1,800 | 96 |
| HHMI | $55,359 | $2.4B | 1,507 | 33 |
| American Association for Cancer Research | $47,714 | $78.9M | 2 | 13 |
| American Society for Cell Biology | $58,656 | $10.0M | 20 | - |
| Histogen | $50,606 | $17.8M | 19 | - |
| SABPA | $68,505 | $62.0M | 7,500 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
aTyr Pharma highest paying jobs
Zippia gives an in-depth look into the details of aTyr Pharma, including salaries, political affiliations, employee data, and more, in order to inform job seekers about aTyr Pharma. The employee data is based on information from people who have self-reported their past or current employments at aTyr Pharma. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by aTyr Pharma. The data presented on this page does not represent the view of aTyr Pharma and its employees or that of Zippia.
aTyr Pharma may also be known as or be related to ATYR PHARMA INC, ATyr Pharma INC., Atyr Pharma, aTYR PHARMA INC, aTyr Pharma, aTyr Pharma Inc and aTyr Pharma, Inc.